Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non–Small Cell Lung Cancer

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr Mutated ◽

Structural Characterizations

Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer

Molecular Medicine Reports ◽

10.3892/mmr.2020.11686 ◽

2020 ◽

Vol 23 (1) ◽

pp. 1-1

Author(s):

Yingjie Lu ◽

Dongliang Bian ◽

Xuelin Zhang ◽

Huibiao Zhang ◽

Zhenghong Zhu

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

The Third

Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.9044 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9044-9044 ◽

Cited By ~ 25

Author(s):

Daniel Shao-Weng Tan ◽

James Chih-Hsin Yang ◽

Natasha B. Leighl ◽

Gregory J. Riely ◽

Lecia V. Sequist ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Phase 1 ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Phase 1 Study ◽

Egfr Tyrosine Kinase Inhibitor

Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study

Lung Cancer ◽

10.1016/j.lungcan.2016.12.002 ◽

2017 ◽

Vol 104 ◽

pp. 58-64 ◽

Cited By ~ 15

Author(s):

Gee-Chen Chang ◽

Chien-Hua Tseng ◽

Kuo-Hsuan Hsu ◽

Chong-Jen Yu ◽

Cheng-Ta Yang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Predictive Factors ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Mutated ◽

Sequence Study

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3321505 ◽

2019 ◽

Author(s):

Yi-Chen Zhang ◽

Zhi-Hong Chen ◽

Xu-Chao Zhang ◽

Chong-Rui Xu ◽

Hong-Hong Yan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr T790m ◽

Clinical Strategy

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

Targeted Oncology ◽

10.1007/s11523-015-0387-4 ◽

2015 ◽

Vol 11 (2) ◽

pp. 167-174 ◽

Cited By ~ 10

Author(s):

J. B. Auliac ◽

C. Fournier ◽

C. Audigier Valette ◽

M. Perol ◽

A. Bizieux ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Tyrosine Kinase Inhibitor Therapy ◽

Egfr Mutated

A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-2595 ◽

2021 ◽

pp. clincanres.2595.2021

Author(s):

Qing Zhou ◽

Lin Wu ◽

Pei Hu ◽

Tongtong An ◽

Jianying Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr T790m

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3341474 ◽

2019 ◽

Author(s):

Yi-Chen Zhang ◽

Zhi-Hong Chen ◽

Xu-Chao Zhang ◽

Chong-Rui Xu ◽

Hong-Hong Yan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr T790m ◽

Clinical Strategy

First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8013 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8013-8013 ◽

Cited By ~ 15

Author(s):

Daniel Shao-Weng Tan ◽

Takashi Seto ◽

Natasha B. Leighl ◽

Gregory J. Riely ◽

Lecia V. Sequist ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Phase I Study ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

HS-10296 – A Novel Third Generation EGFR Tyrosine Kinase Inhibitor: Results of the First-in-Human Phase 1 Trial in Patients with Previously Treated EGFR Mutant Advanced Non-Small-Cell Lung Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3495608 ◽

2019 ◽

Author(s):

James Chih-Hsin Yang ◽

D. Ross Camidge ◽

Cheng-Ta Yang ◽

Jianying Zhou ◽

Renhua Guo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Phase 1 ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Previously Treated ◽

Egfr Mutant

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Mutant